Gene therapy for infantile malignant osteopetrosis : review of pre-clinical research and proof-of-concept for phenotypic reversal
© 2020 The Author(s)..
Infantile malignant osteopetrosis is a devastating disorder of early childhood that is frequently fatal and for which there are only limited therapeutic options. Gene therapy utilizing autologous hematopoietic stem and progenitor cells represents a potentially advantageous therapeutic alternative for this multisystemic disease. Gene therapy can be performed relatively rapidly following diagnosis, will not result in graft versus host disease, and may also have potential for reduced incidences of other transplant-related complications. In this review, we have summarized the past sixteen years of research aimed at developing a gene therapy for infantile malignant osteopetrosis; these efforts have culminated in the first clinical trial employing lentiviral-mediated delivery of TCIRG1 in autologous hematopoietic stem and progenitor cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Molecular therapy. Methods & clinical development - 20(2021) vom: 12. März, Seite 389-397 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moscatelli, Ilana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autosomal recessive osteopetrosis |
|---|
| Anmerkungen: |
Date Revised 13.02.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.omtm.2020.12.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321353412 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321353412 | ||
| 003 | DE-627 | ||
| 005 | 20231225175628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.omtm.2020.12.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1071.xml |
| 035 | |a (DE-627)NLM321353412 | ||
| 035 | |a (NLM)33575431 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moscatelli, Ilana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gene therapy for infantile malignant osteopetrosis |b review of pre-clinical research and proof-of-concept for phenotypic reversal |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.02.2021 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 The Author(s). | ||
| 520 | |a Infantile malignant osteopetrosis is a devastating disorder of early childhood that is frequently fatal and for which there are only limited therapeutic options. Gene therapy utilizing autologous hematopoietic stem and progenitor cells represents a potentially advantageous therapeutic alternative for this multisystemic disease. Gene therapy can be performed relatively rapidly following diagnosis, will not result in graft versus host disease, and may also have potential for reduced incidences of other transplant-related complications. In this review, we have summarized the past sixteen years of research aimed at developing a gene therapy for infantile malignant osteopetrosis; these efforts have culminated in the first clinical trial employing lentiviral-mediated delivery of TCIRG1 in autologous hematopoietic stem and progenitor cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a autosomal recessive osteopetrosis | |
| 650 | 4 | |a gene therapy | |
| 650 | 4 | |a hematopoietic stem and progenitor cells | |
| 650 | 4 | |a infantile malignant osteopetrosis | |
| 650 | 4 | |a lentivirus | |
| 650 | 4 | |a osteoclast disorders | |
| 700 | 1 | |a Almarza, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Schambach, Axel |e verfasserin |4 aut | |
| 700 | 1 | |a Ricks, David |e verfasserin |4 aut | |
| 700 | 1 | |a Schulz, Ansgar |e verfasserin |4 aut | |
| 700 | 1 | |a Herzog, Christopher D |e verfasserin |4 aut | |
| 700 | 1 | |a Henriksen, Kim |e verfasserin |4 aut | |
| 700 | 1 | |a Askmyr, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, Jonathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Johan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular therapy. Methods & clinical development |d 2014 |g 20(2021) vom: 12. März, Seite 389-397 |w (DE-627)NLM23764147X |x 2329-0501 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2021 |g day:12 |g month:03 |g pages:389-397 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.omtm.2020.12.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2021 |b 12 |c 03 |h 389-397 | ||